MedTrace Logo

ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance

NCT07722819 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-07-23

No results posted yet for this study

Summary

Collect 300 esophageal cancer tissue specimens, including cancer tissue and serum, from a biological sample bank. Collect clinical information on esophageal cancer, including gender, age, time of diagnosis, time of death, treatment information, TNM staging, tumor size, location, etc. DNA sequencing was performed on 300 collected esophageal cancer samples, divided into mutant and wild-type types. Perform immunohistochemistry on tissue slices and observe the expression of P53 mutant protein. ELISA was used to study the expression of serum anti-P53 autoantibodies. Process these data and use them to classify subtypes of esophageal cancer. Associate each subtype with clinical information, analyze the characteristics of each subtype, such as the multidimensional features of P53 and treatment correlation analysis, and the correlation between P53 multidimensional features and survival.

Conditions

  • P53 Mutation in Esophageal Cancer

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Ling Zhiqiang

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-21
Primary Completion
2026-07-13
Completion
2026-07-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07722819 on ClinicalTrials.gov